US moves to restrict Chinese genomics firms over forced labour concerns

The United States has unveiled proposed rules designed to curb investment flows and restrict imports from Chinese genomics and biotechnology firms, marking an escalation in technology trade tensions between Washington and Beijing.

The restrictions, introduced by the Trump administration, reflect growing scrutiny of Chinese biotech companies' supply chains and operational practices. Officials have flagged concerns over alleged forced labour in the sector, prompting policymakers to consider more stringent oversight mechanisms.

The proposed regulations would limit US investment in Chinese biotechnology enterprises and establish barriers to importing genomic materials and related products. Such measures are expected to significantly impact Chinese firms' access to American capital and markets, disrupting established commercial relationships.

The move reflects broader US strategy to reduce reliance on Chinese technology sectors deemed sensitive to national security interests. Biotechnology and genomics research carry strategic implications for healthcare, agriculture, and defence applications, making them focal points for trade restrictions.

China's genomics sector, which has grown into a global competitor over recent years, is likely to face operational challenges should the restrictions take effect. Industry observers anticipate ripple effects across supply chains serving markets throughout Asia-Pacific, including Malaysia.